STOCK TITAN

Artelo Biosciences (ARTL) awards 136-share stock option grant

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Artelo Biosciences director Gregory Reyes received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share, expiring July 17, 2036. All options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Reyes Gregory
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 136 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 136 shares (Direct)
Footnotes (1)
  1. F1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
Stock options granted 136 shares Director stock option grant covering common stock
Exercise price $1.15 per share Exercise price of the granted stock options
Expiration date July 17, 2036 Option expiration for the director grant
Vesting Commencement Date July 17, 2026 Defined as the Vesting Commencement Date for the option
Stock Option (right to buy) financial
"Security title reported as Stock Option (right to buy)."
Vesting Commencement Date financial
""Vesting Commencement Date" shall mean July 17, 2026."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
Service Provider financial
"Subject to the Reporting Person continuing to be a Service Provider..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Artelo Biosciences (ARTL) report for Gregory Reyes?

Artelo Biosciences reported that director Gregory Reyes received a grant of stock options covering 136 shares of common stock. The options carry a $1.15 exercise price per share, expire on July 17, 2036, and vest in full based on future service and meeting timing conditions.

How many Artelo Biosciences (ARTL) shares are covered by Gregory Reyes’s new options?

The grant to director Gregory Reyes covers 136 shares of Artelo Biosciences common stock through stock options. These options represent the right to buy the underlying shares once vested, subject to the specified vesting schedule and his continued status as a service provider.

What is the exercise price of Gregory Reyes’s Artelo Biosciences (ARTL) stock options?

The stock options granted to director Gregory Reyes have an exercise price of $1.15 per share. This is the fixed price at which he may purchase the 136 underlying common shares after the options vest, provided he remains a qualifying service provider.

When do Gregory Reyes’s Artelo Biosciences (ARTL) options vest?

All of Gregory Reyes’s options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting. Vesting is conditioned on his continued status as a service provider through the applicable date.

What is the expiration date of the stock options granted to Gregory Reyes at Artelo Biosciences (ARTL)?

The options granted to director Gregory Reyes expire on July 17, 2036. After this expiration date, any unexercised portion of the 136-share option grant will lapse, even if it has vested, consistent with the long-term nature of typical director equity compensation.

Are Gregory Reyes’s new Artelo Biosciences (ARTL) options immediately exercisable?

No. Gregory Reyes’s options vest 100% only after specific conditions are met: continued service through the vesting date and the earlier of one year after July 17, 2026 or the day before the next annual stockholder meeting. Exercise generally follows vesting and remains subject to plan terms.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reyes Gregory

(Last)(First)(Middle)
C/O ARTELO BIOSCIENCES, INC.
505 LOMAS SANTA FE, SUITE 160

(Street)
SOLANA BEACH CALIFORNIA 92075

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.1507/17/2026A136 (1)07/17/2036Common Stock136$0.00136D
Explanation of Responses:
1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
/s/ Gregory D. Gorgas, as Attorney-in-Fact07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)